Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962989 | 0.94 | ALDH1A1 (0.46) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL18235508 | 0.94 | ALDH1A1 (0.36) | ALDH1A1SOAT1CTSAACHELMNA | |
| SCHEMBL14283708 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL18239574 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SOAT1 | |
| SCHEMBL18235516 | 0.81 | ALDH1A1 (0.34) | ALDH1A1SOAT1LMNAHSD17B10 | |
| SCHEMBL18239578 | 0.81 | CTSA (0.34) | CTSAACHE | |
| SCHEMBL17034257 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL18307667 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL28404629 | 0.78 | ALDH1A1 (0.60) | ALDH1A1SOAT1LMNAHSD17B10ALOX15 | |
| SCHEMBL18239625 | 0.78 | LMNA (0.32) | CTSAACHELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333024-A1 | OXABICYCLOHEPTANE PRODRUGS | UGT2B7, UGT1A6, UGT1A1 | ALDH1A1 259/4885SOAT1 1271/4885CTSA 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.